The protein degradation-focused drug developer, a spinout from Dana-Farber Cancer Institute, received $150m in series B funding and $20m in venture debt.

C4 Therapeutics, a US-based small molecule drug developer spun out of the Harvard-affiliated Dana-Farber Cancer Institute, completed a $170m financing round yesterday. Investment firm Cobro Ventures and hedge fund Perceptive Advisors co-led the $150m series B equity portion of the round, which also featured undisclosed existing investors, while Perceptive Advisors also supplied $20m in debt…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.